<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577159</url>
  </required_header>
  <id_info>
    <org_study_id>DAPHNIS</org_study_id>
    <nct_id>NCT02577159</nct_id>
  </id_info>
  <brief_title>Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)</brief_title>
  <acronym>DAPHNIS</acronym>
  <official_title>Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will investigate whether dapagliflozin (FORXIGA) might improve lipoprotein
      metabolism as well as hyperglycemia in Japanese patients with type II diabetes mellitus whose
      HbA1c levels are less than 7.0% (from 20 to 65 years of age). The investigators will examine
      changes of fasting lipoprotein profile including TG, TC, HDL-C, apoB-48 and RemL-C before and
      after the 8 weeks administration of dapagliflozin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators will investigate whether dapagliflozin (FORXIGA) might
      improve lipoprotein metabolism as well as hyperglycemia in Japanese patients with type II
      diabetes mellitus. Primary Objective is to examine changes of fasting lipoprotein profile by
      the administration of dapagliflozin; Concentrations of apoB-48 and RemL-C. Secondary
      Objectives are; to examine changes of fasting glucose and HbA1c (NGSP) level by the
      administration of dapagliflozin, to examine changes of fasting lipid profile by the
      administration of dapagliflozin; Concentrations of TG, TC, HDL-C and LDL-C, to examine
      changes of fractions of free fatty acids, protein mass of LPL, and lipoprotein profile
      assessed by the HPLC by the administration of dapagliflozin, to examine changes of biomarkers
      for renal and hepatic function by the administration of dapagliflozin, and to examine the
      frequency of adverse effects by the administration of dapagliflozin. This study is open-label
      study and contains patients who are diabetes mellitus of from 20 to 65 years of age and their
      Patients who have not achieve the clinical target of the glycemic control (less than 7.0% in
      HbA1c).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 1, 2015</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in fasting lipoprotein profiles</measure>
    <time_frame>at four and eight weeks after the administration of dapagliflozin</time_frame>
    <description>Changes in fasting lipoprotein profiles including concentrations of apoA-1, apoA-2, apoB, apoB-48, apoC-2, apoC-3, apoE, RemL-C, free-fatty acids profile, LPL protein mass and lipoprotein profile assessed by the HPLC at four and eight weeks after the administration of dapagliflozin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting lipid profiles</measure>
    <time_frame>at four and eight weeks after the administration of dapagliflozin</time_frame>
    <description>Changes in fasting lipid profiles including concentrations of triglyceride(TG), total cholesterol(TC), HDL-cholesterol (HDL-C) and LDL-C at four and eight weeks after the administration of dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood glucose and HbA1c</measure>
    <time_frame>at four and eight weeks after the administration of dapagliflozin</time_frame>
    <description>Changes in fasting blood glucose and HbA1c at four and eight weeks after the administration of dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin and adiponectin</measure>
    <time_frame>at four and eight weeks after the administration of dapagliflozin</time_frame>
    <description>Changes in other clinical profiles including concentrations of insulin and adiponectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse side effects</measure>
    <time_frame>at four and eight weeks after the administration of dapagliflozin</time_frame>
    <description>Frequency of adverse side effects at four and eight weeks after the administration of dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biomarkers for renal and hepatic function</measure>
    <time_frame>four and eight weeks after the administration of dapagliflozin.</time_frame>
    <description>Changes in biomarkers for renal and hepatic function at four and eight weeks after the administration of dapagliflozin.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetic patients who met the inclusion/exclusion criteria. Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>conventional treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with type 2 diabetes mellitus of from 20 to 65 years of age.

          -  Patients who have not achieve the clinical target of the glycemic control (less than
             7.0% in HbA1c).

          -  Patients who received the diet therapy, the exercise therapy or the following
             anti-diabetic drugs in addition to the diet and/or exercise therapy (up to two drugs)
             with dosage stable for 8 weeks prior to entry.

          -  Sulfonylurea (Glymepiride 2mg/day or less, Glibenclamide 1.25mg/day or less,
             Gliclazide 40mg/day or less)

          -  Thiazolidine (Actos)

          -  Biguanide (Metformin, Buformin)

          -  alpha-glucosidase inhibitor (Voglibose, Miglitol, Acarbose)

          -  DPP4 inhibitors (Sitagliptin, Linagliptin, Anagliptin, Teneligliptin, Alogliptin,
             Saxagliptin)

          -  Informed consent to participate in the study prior to any study procedures.

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Moderate or severe renal dysfunction (eGFR&lt;45 ml/min/1.73m2 or hemodialysis)

          -  Severe hepatic insufficiency (AST and/or ALT &gt;3x upper limit of normal)

          -  Adrenal insufficiency or pituitary gland dysfunction

          -  Malnourishment, starvation, irregular dietary intake, poor dietary intake,
             debilitating condition or a severe muscle movement

          -  Volume depleted patients; concomitant medication such as loop diuretics.

          -  Excessive alcohol intake (&gt;60g daily)

          -  SGLT2 inhibitors such as dapagliflozin are already administered

          -  Contraindication with dapagliflozin

          -  Start a new medication of statins, fibrates, ezetimibe or probucol within a month

          -  Females who are likely to be pregnant, during pregnancy or lactating

          -  Participants in other clinical trials

          -  Inability to communicate and comply with all study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shizuya Yamashita, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka University Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daisaku Masuda, MD, PhD</last_name>
    <phone>+81-6-6879-3633</phone>
    <email>masuda@cardiology.med.osaka-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka Central Hospital</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka</state>
        <zip>5300001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daisaku Masuda, MD, PhD</last_name>
      <phone>+647955505</phone>
      <email>masuda@cardiology.med.osaka-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>5650871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisaku Masuda, MD, PhD</last_name>
      <phone>+81668793633</phone>
      <email>masuda@cardiology.med.osaka-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Masahiro Koseki, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryota Kawase, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takuya Kobayashi, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayami Saga</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masumi Asaji</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kazuhiro Nakatani, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masami Sairyou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takeshi Okada, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hibiki Matsuda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Makoto Nishida, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tohru Ohama, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sousei Hospital</name>
      <address>
        <city>Kadoma, Osaka</city>
        <zip>5710025</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisaku Masuda, MD, PhD</last_name>
      <phone>+728851711</phone>
      <email>masuda@cardiology.med.osaka-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Hanada H, Mugii S, Okubo M, Maeda I, Kuwayama K, Hidaka Y, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Yuasa-Kawase M, Nakatani K, Tsubakio-Yamamoto K, Masuda D, Ohama T, Matsuyama A, Ishigami M, Nishida M, Komuro I, Yamashita S. Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism. Clin Chim Acta. 2012 Jan 18;413(1-2):160-5. doi: 10.1016/j.cca.2011.09.013. Epub 2011 Sep 19.</citation>
    <PMID>21958700</PMID>
  </reference>
  <reference>
    <citation>Masuda D, Sakai N, Sugimoto T, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M, Ishigami M, Masuda Y, Matsuyama A, Komuro I, Yamashita S. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia. J Atheroscler Thromb. 2011;18(12):1062-70. Epub 2011 Sep 24.</citation>
    <PMID>21946533</PMID>
  </reference>
  <reference>
    <citation>Okubo M, Hanada H, Matsui M, Hidaka Y, Masuda D, Sakata Y, Yamashita S. Serum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuria. J Atheroscler Thromb. 2014;21(9):974-82. Epub 2014 Jun 2.</citation>
    <PMID>24882621</PMID>
  </reference>
  <reference>
    <citation>Mugii S, Hanada H, Okubo M, Masuda D, Takeoka K, Hidaka Y, Ohama T, Matsuyama A, Nakagawa-Toyama Y, Nishida M, Ishigami M, Komuro I, Yamashita S. Thyroid function influences serum apolipoprotein B-48 levels in patients with thyroid disease. J Atheroscler Thromb. 2012;19(10):890-6. Epub 2012 Jul 4.</citation>
    <PMID>22786447</PMID>
  </reference>
  <reference>
    <citation>Nakatani K, Sugimoto T, Masuda D, Okano R, Oya T, Monden Y, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Komuro I, Yamashita S. Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels. Atherosclerosis. 2011 Sep;218(1):226-32. doi: 10.1016/j.atherosclerosis.2011.05.009. Epub 2011 May 18.</citation>
    <PMID>21641598</PMID>
  </reference>
  <reference>
    <citation>Masuda D, Sugimoto T, Tsujii K, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Kawamoto T, Matsuyama A, Sakai N, Komuro I, Yamashita S. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest. 2012 Sep;42(9):992-9. doi: 10.1111/j.1365-2362.2012.02687.x. Epub 2012 May 15.</citation>
    <PMID>22587365</PMID>
  </reference>
  <reference>
    <citation>Ji L, Ma J, Li H, Mansfield TA, T'joen CL, Iqbal N, Ptaszynska A, List JF. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014 Jan 1;36(1):84-100.e9. doi: 10.1016/j.clinthera.2013.11.002. Epub 2013 Dec 28.</citation>
    <PMID>24378206</PMID>
  </reference>
  <reference>
    <citation>Kaku K, Maegawa H, Tanizawa Y, Kiyosue A, Ide Y, Tokudome T, Hoshino Y, Yang J, Langkilde AM. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther. 2014 Dec;5(2):415-33. doi: 10.1007/s13300-014-0086-7. Epub 2014 Oct 24.</citation>
    <PMID>25341477</PMID>
  </reference>
  <reference>
    <citation>Bolinder J, Ljunggren Ã–, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.</citation>
    <PMID>22238392</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sodium-glucose cotransporter 2 inhibitor</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>remnants</keyword>
  <keyword>apolipoprotein B-48</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

